A blog about the intersection of medicine and business, produced by the members of the Medical Consumerism seminar at the University of Minnesota.
Saturday, July 10, 2010
Death blow to Avandia?
An FDA official has delivered a brutally critical review of Avandia, finding that GSK failed to count instances where Avandia was related to serious heart problems. The review could mean the death of the controversial drug next week, when a panel of experts meets to decide whether Avandia should be withdrawn from the market. Read more in the Times.